Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Authors
Keywords
-
Journal
LEUKEMIA
Volume 37, Issue 6, Pages 1175-1185
Publisher
Springer Science and Business Media LLC
Online
2023-05-04
DOI
10.1038/s41375-023-01920-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
- (2023) Doris K. Hansen et al. JOURNAL OF CLINICAL ONCOLOGY
- Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months
- (2023) João Malato et al. LANCET INFECTIOUS DISEASES
- Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
- (2023) Jing Zou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial
- (2023) Sian E. Faustini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
- (2023) Charalampos Filippatos et al. Viruses-Basel
- P55 MULTIPLE MYELOMA AND SARS-COV-2 INFECTION: AN EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA) OF 1,221 PATIENTS THROUGH THE DIFFERENT PHASES OF COVID-19 PANDEMIC
- (2023) P. Musto et al. HemaSphere
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
- (2022) Laura Vangeel et al. ANTIVIRAL RESEARCH
- Booster BNT162b2 Optimizes SARS-CoV-2 Humoral Response in Myeloma Patients; the Negative Effect of anti-BCMA therapy
- (2022) Evangelos Terpos et al. BLOOD
- COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research
- (2022) Lindsey Wang et al. BLOOD REVIEWS
- Depletion of CD38 ‐positive regulatory T cells by anti‐CD38 monoclonal antibodies induces a durable response to SARS‐CoV ‐2 vaccination in patients with plasma cell dyscrasia
- (2022) Toshiki Terao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
- (2022) Karthik Ramasamy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titers
- (2022) O. Šušol et al. BRITISH JOURNAL OF HAEMATOLOGY
- Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
- (2022) Meera Mohan et al. Clinical Lymphoma Myeloma & Leukemia
- Serological response following anti-SARS-CoV-2 vaccination in hematopoietic stem cell transplantation patients depends upon time from transplant, type of transplant and “booster” dose
- (2022) Immacolata Attolico et al. HAEMATOLOGICA
- Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
- (2022) Toshiki Terao et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
- (2022) Thomas Hueso et al. LEUKEMIA
- Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
- (2022) Daniel Re et al. Nature Communications
- Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
- (2022) Noopur S Raje et al. Lancet Haematology
- Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
- (2022) Csilla Várnai et al. JAMA Network Open
- Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
- (2022) Sabine Haggenburg et al. Blood Advances
- COVID-19: impact of vaccination in myeloma patients
- (2022) E. Hoornaert et al. ANNALS OF HEMATOLOGY
- Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
- (2022) Adolfo Aleman et al. CANCER CELL
- Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
- (2022) Julius C. Enssle et al. CANCER CELL
- COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis
- (2022) Yusuke Ito et al. Clinical Lymphoma Myeloma & Leukemia
- Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel
- (2022) Corrado Girmenia et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
- (2022) Ajay K. Nooka et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study
- (2022) Anthony Rooney et al. Journal of Hematology & Oncology
- SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease
- (2022) Angelika Wagner et al. Frontiers in Immunology
- Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
- (2022) Maggie Li et al. Blood Advances
- Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
- (2022) Ola Blennow et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients
- (2022) Yann Nguyen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Neutralizing antibody responses against SARS‐CoV ‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination
- (2022) Al‐Ola Abdallah et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patients
- (2022) Loredana Pettine et al. HEMATOLOGICAL ONCOLOGY
- Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV
- (2022) Patrizia Zappasodi et al. HEMATOLOGICAL ONCOLOGY
- Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case–control study
- (2022) A. Oliva et al. INFECTION
- Response to anti‐SARS‐CoV ‐2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients
- (2022) Joanna Zaleska et al. INTERNATIONAL JOURNAL OF CANCER
- High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination
- (2022) Lauren C. Shapiro et al. LEUKEMIA & LYMPHOMA
- Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination
- (2022) Carol Gung et al. Frontiers in Oncology
- Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
- (2022) Eugenia Abella et al. Life Science Alliance
- Risk factors for severe infection and mortality In patients with COVID ‐19 in patients with multiple myeloma and AL amyloidosis
- (2022) Matthew Ho et al. AMERICAN JOURNAL OF HEMATOLOGY
- Antibody and T‐cell responses by ultra‐deep T‐cell receptor immunosequencing after COVID ‐19 vaccination in patients with plasma cell dyscrasias
- (2022) Alfred Chung et al. BRITISH JOURNAL OF HAEMATOLOGY
- P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
- (2022) Vassiliki Spiliopoulou et al. Clinical Lymphoma Myeloma & Leukemia
- Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
- (2022) Carlos K H Wong et al. LANCET
- Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
- (2022) Paola Storti et al. OncoImmunology
- Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19
- (2022) Sabine Haggenburg et al. JAMA Oncology
- Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indices
- (2022) Panagiotis G. Asteris et al. CLINICAL IMMUNOLOGY
- WITHDRAWN: Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
- (2022) Xia Wang et al. JOURNAL OF INFECTION
- Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma
- (2022) Dian Zhou et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
- (2022) Giuseppe Bruno et al. Viruses-Basel
- Antibodies and bispecifics for multiple myeloma: effective effector therapy
- (2022) Christopher Cipkar et al. Hematology-American Society of Hematology Education Program
- Cellular therapy for multiple myeloma: what's now and what's next
- (2022) Paula Rodriguez-Otero et al. Hematology-American Society of Hematology Education Program
- Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer
- (2022) Lennard Y. W. Lee et al. JAMA Oncology
- Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
- (2022) Margherita Rosati et al. Cancers
- Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
- (2022) Nando Reza Pratama et al. Vaccines
- mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
- (2022) Vivek P. Chavda et al. Vaccines
- Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
- (2022) Grace Lai-Hung Wong et al. JAMA Network Open
- Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis
- (2022) Nipat Chuleerarux et al. Blood Advances
- The potential link between Covid‐19 and multiple myeloma: A new saga
- (2022) Hayder M. Al‐Kuraishy et al. Immunity Inflammation and Disease
- Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
- (2022) Jon Salmanton-García et al. HemaSphere
- Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
- (2022) Andrea Keppler-Hafkemeyer et al. Nature Cancer
- Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
- (2021) Akshay Sharma et al. Lancet Haematology
- Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
- (2021) Andrew R. Branagan et al. Blood Advances
- Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose
- (2021) Evangelos Terpos et al. BLOOD
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
- (2021) Fulvia Pimpinelli et al. Journal of Hematology & Oncology
- Epidemiology and organ specific sequelae of post-acute COVID19: A Narrative Review
- (2021) Eleni Korompoki et al. JOURNAL OF INFECTION
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
- (2021) Sarah Bird et al. Lancet Haematology
- Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
- (2021) Ian McDonald et al. npj Vaccines
- Antibody response to COVID ‐19 mRNA vaccine ( Comirnaty ) in myeloma patients treated with high‐dose melphalan and/or immunotherapy
- (2021) Sandra Lockmer et al. AMERICAN JOURNAL OF HEMATOLOGY
- Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response
- (2021) Heinz Ludwig et al. AMERICAN JOURNAL OF HEMATOLOGY
- BNT162b2 COVID ‐19 vaccine is significantly less effective in patients with hematologic malignancies
- (2021) Katrin Herzog Tzarfati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy
- (2021) Binod Dhakal et al. BLOOD
- The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b2
- (2021) Francesco Marchesi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine
- (2021) Maria Gavriatopoulou et al. BRITISH JOURNAL OF HAEMATOLOGY
- Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients
- (2021) Magdalena Benda et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy
- (2021) Wei Yee Chan et al. BRITISH JOURNAL OF HAEMATOLOGY
- COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma
- (2021) Karthik Ramasamy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
- (2021) Irit Avivi et al. BRITISH JOURNAL OF HAEMATOLOGY
- COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
- (2021) Francesco Passamonti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
- (2021) Oliver Van Oekelen et al. CANCER CELL
- Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
- (2021) Sidse Ehmsen et al. CANCER CELL
- Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
- (2021) Samuel D. Stampfer et al. LEUKEMIA
- Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies
- (2021) Daniel Re et al. LEUKEMIA & LYMPHOMA
- The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
- (2021) Evangelos Terpos et al. Blood Cancer Journal
- Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
- (2021) Kazimieras Maneikis et al. Lancet Haematology
- Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
- (2021) Susanne Ghandili et al. Cancers
- Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients
- (2021) Martina Chiarucci et al. Frontiers in Oncology
- Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
- (2021) Mounzer E Agha et al. Open Forum Infectious Diseases
- Late‐onset hematological complications post COVID ‐19: An emerging medical problem for the hematologist
- (2021) Eleni Korompoki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Distinct neutralization profile of spike variants by antibodies induced upon SARS‐CoV ‐2 infection or vaccination
- (2021) Margherita Rosati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Attenuated humoral immune response following anti‐SARS‐CoV ‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis
- (2021) Neta Schiller Salton et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
- (2021) Soledad Henriquez et al. BLOOD
- Effectiveness of the BNT162b2mRNA Covid-19 Vaccine in Patients with Hematological Neoplasms
- (2021) Moshe Mittelman et al. BLOOD
- Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
- (2021) Julius C. Enßle et al. BLOOD
- Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma
- (2021) Ross S. Greenberg et al. BMC CANCER
- Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
- (2021) Marco Salvini et al. BONE MARROW TRANSPLANTATION
- Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors
- (2021) Wei Yee Chan et al. BRITISH JOURNAL OF HAEMATOLOGY
- T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
- (2021) Vincenzo Marasco et al. BRITISH JOURNAL OF HAEMATOLOGY
- Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
- (2021) Adolfo Aleman et al. CANCER CELL
- Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia
- (2021) Yoshinobu Konishi et al. CANCER CELL
- COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination
- (2021) Mansi R. Shah et al. Clinical Lymphoma Myeloma & Leukemia
- Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis
- (2021) Nico Gagelmann et al. HAEMATOLOGICA
- COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
- (2021) Livio Pagano et al. Journal of Hematology & Oncology
- Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls
- (2021) Samuel Bitoun et al. Journal of Hematology & Oncology
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- (2021) Robert L. Gottlieb et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of COVID-19 in patients with multiple myeloma based on a global data network
- (2021) J. Martinez-Lopez et al. Blood Cancer Journal
- SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
- (2021) Nicola Sgherza et al. Blood Cancer Journal
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
- (2021) Heinz Ludwig et al. Lancet Haematology
- Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
- (2021) Evangelos Terpos et al. JAMA Oncology
- Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
- (2021) Susanne Ghandili et al. Journal of Clinical Medicine
- Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma
- (2021) Lindsey Wang et al. JAMA Network Open
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
- (2021) Deborah Cromer et al. Lancet Microbe
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.
- (2020) Gordon Cook et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
- (2020) Evangelos Terpos et al. LEUKEMIA
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak
- (2020) Mengyuan Dai et al. Cancer Discovery
- Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany
- (2020) Monika Engelhardt et al. HAEMATOLOGICA
- A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
- (2020) Bo Wang et al. Journal of Hematology & Oncology
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- (2020) Francesco Passamonti et al. Lancet Haematology
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
- (2020) Lennard Y W Lee et al. LANCET ONCOLOGY
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
- (2020) Heinz Ludwig et al. LEUKEMIA
- Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany
- (2020) Khalid Shoumariyeh et al. Cancer Medicine
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
- (2020) Abi Vijenthira et al. BLOOD
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
- (2020) Ajai Chari et al. BLOOD
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
- (2019) Hareth Nahi et al. PLoS One
- Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
- (2018) Min Chen et al. ANNALS OF HEMATOLOGY
- Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study
- (2018) Rasmus Sørrig et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
- (2014) C. Blimark et al. HAEMATOLOGICA
- The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
- (2009) M. Basler et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now